Clinical Pipeline Unleashing the immune system’s potential in cancer and autoimmune disease

View the current Immutep clinical oncology pipeline and discover how our immunotherapy technology is being used for autoimmune and cancer treatments.

Company Overview Our Science Clinical Pipeline Investors & Media Contact Follow Us

Metastatic Urothelial Carcinoma – Update from investigator-initiated INSIGHT-005 trial Autoimmune Diseases – Update from IMP761 first-in-human Phase I trial Additional Updates – …

T wo ACT ive I mmunotherapies-004 (TACTI-004) is an active trial that is recruiting patients and is being conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). TACTI …

Discover more about Immutep’s Immunotherapy Portfolio through Our Clinical Pipeline and Company Overview

Oct 9, 2025 · Dec 08, 2025 Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

Our Science Our Science Posters & Publications Clinical Pipeline Clinical Pipeline Clinical Trials TACTI-004 Phase III

Nov 22, 2018 · Global Webcast Slides for TACTI-003 Positive Data in Patients with Negative PD-L1 Expression (Cohort B)

Pure-play LAG-3 company with deep pipeline in oncology & autoimmune diseases: Multiple LAG-3 Programs – Four clinical-stage assets and one preclinical program